As biologics programs advance toward clinical and commercial manufacturing, the margin for error continues to narrow. Misalignment across process knowledge, site differences, and data handoffs can introduce risk and impact readiness for PPQ.
Register to join our COO, Richard Richieri for this upcoming webinar.
Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline TUSTIN, CA, May 18, 2026 — Avid Bioservices, a leading biologics CDMO, today announced the […]
Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programs TUSTIN, Calif., May 11, 2026 — Avid Bioservices, Inc., a dedicated biologics contract development and […]
Press Release: Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California Costa Mesa, Calif. – [February 24, 2026] – Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand […]
Seasoned business and finance leader brings growth mindset to support Avid’s next phase expansion and client execution TUSTIN, Calif. — [January 15, 2026] — Avid Bioservices, a leading contract development […]
The newly created role marks a major step in CEO Kenneth Bilenberg’s vision to scale Avid for its next chapter of growth. TUSTIN, Calif., November 10, 2025 – Avid […]
Tustin, CA, USA – September 15, 2025 – Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new […]
SOUTH SAN FRANCISCO, California – August 05, 2025 – Privately held CHO Plus, Inc. announced today a project agreement awarded from the Biomedical Advanced Research and Development Authority’s (BARDA) Biopharmaceutical […]